| Tyvyt (sintilimab) / Eli Lilly |
ChiCTR2100049361: Phase II Single Arm Study of Combination Sintilimab and Platinum-based Chemotherapy in Patients with Recurrent, Persistent, or Metastatic Cervical Cancer |
|
|
| Not yet recruiting | 2 | 20 | | Sindilizumab combined with chemotherapy | Hu'nan Cancer Hospital; Hu'nan Cancer Hospital, Company sponsored | Cervical Cancer | | | | |
NCT03619824: PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 40 | RoW | Sintilimab, IBI308, PD-1 antibody, Gemcitabine, Cisplatin, DDP, intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Innovent Biologics (Suzhou) Co. Ltd. | Nasopharyngeal Neoplasms | 10/19 | 03/24 | | |
| Active, not recruiting | 2 | 40 | RoW | HAIC+PD1, Sintilimab (IBI308), FOLFOX-HAIC, HAIC | Sun Yat-sen University, Innovent Biologics, Inc. | Hepatocellular Carcinoma | 07/20 | 12/24 | | |
ChiCTR1800018861: Phase II Study for Maintenance IBI308 in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). |
|
|
| Recruiting | 2 | 43 | | IBI308 | Shandong Cancer Hospital; Shandong Cancer Hospital, Cinda biopharmaceutical co., Ltd. | lung cancer | | | | |
CARTAI, NCT03732430: CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients |
|
|
| Recruiting | 2 | 45 | RoW | IBI308 | Taizhou Hospital | Thoracic Malignancies | 12/20 | 05/22 | | |
NIBCUN, NCT03872661: Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC |
|
|
| Recruiting | 2 | 36 | RoW | IBI308, Sintilimab, Bevacizumab, Avastin, Pemetrexed, Pemetrexed disodium, Carboplatin, CBP, Thoracic surgery | Sun Yat-sen University | Lung Cancer Stage III | 03/21 | 03/24 | | |
NCT06250894: Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction |
|
|
| Recruiting | 2 | 32 | RoW | PD-1inhibitor | Wuhan Union Hospital, China | PD-1, Neoadjuvant Chemoradiotherapy, Gastroesophageal Junction Cancer | 06/24 | 03/25 | | |
ChiCTR2100045659: Sintilimab in combination with paclitaxel and cisplatin as neoadjuvant therapy in patients with locally advanced esophageal cancer: a single-center, single-arm, exploratory clinical study |
|
|
| Recruiting | 2 | 30 | | sintilimab in combination with paclitaxel and cisplatin neoadjuvant therapy | Fujian Medical University Union Hospital; Fujian Union Hospital, Innovent Biologics Co., Ltd. | esophagus cancer | | | | |
ChiCTR2100043184: Phase II clinical study of Sintilimab combined with concurrent chemoradiotherapy in patients with limited stage small cell lung cancer |
|
|
| Recruiting | 2 | 22 | | Sintilimab combined with concurrent chemoradiotherapy | Shandong Cancer Hospital; Shandong Cancer Hospital, Taishan Scholars Young Expert Project | Small Cell Lung Cancer | | | | |
NCT03985046: Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC |
|
|
| Completed | 2 | 75 | RoW | Sintilimab plus Chemotherapy | Fudan University | Esophageal Squamous Cell Carcinoma | 05/21 | 12/22 | | |
NCT03989336: An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer |
|
|
| Completed | 2 | 84 | RoW | Manganese Chloride, nab-paclitaxel, Paclitaxel For Injection (Albumin Bound), Platinum chemotherapy, Sintilimab, anti-PD-1 antibody; PD-1 inhibitor | Chinese PLA General Hospital | Ovarian Cancer | 05/22 | 12/23 | | |
NCT04189094: Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC |
|
|
| Not yet recruiting | 2 | 140 | NA | Sintilimab, Etoposide, VP-16, Cisplatin, DDP, radiotherapy | Zhejiang Cancer Hospital, First Affiliated Hospital, Sun Yat-Sen University, The Affiliated Hospital of Guangdong Medical College, First People's Hospital of Foshan | Small Cell Lung Cancer Limited Stage | 07/21 | 07/23 | | |
NCT04312204: Clinical Trial of Sintilimab Combined With Gemcitabine/Carboplatin Regimen in the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-like Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Sintilimab combined with Gemcitabine and Carboplatin | Zhou Chengzhi | Primary Pulmonary Lymphoepithelioma-like Carcinoma, Lung Cancer | 08/21 | 08/22 | | |
NCT04518982: Sintilimab and Lenalidomide as a Treatment for CAEBV |
|
|
| Recruiting | 2 | 51 | RoW | Sintilimab and lenalidomide, Sintilimab placebo and lenalidomide placebo | Zhao Wang | CAEBV | 08/21 | 08/21 | | |
NCT04098796: PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Anti-PD-1 antibody, XELOX | China Medical University, China | Gastric or Gastroesophageal Junction Adenocarcinoma, AFP | 09/21 | 09/21 | | |
| Active, not recruiting | 2 | 60 | RoW | sintilimab, IBI308, PD-1 antibody, pemetrexed, Carboplatin, albumin-bound paclitaxel | Second Affiliated Hospital, School of Medicine, Zhejiang University | Non-small Cell Lung Cancer | 11/21 | 07/23 | | |
ChiCTR1900027161: Phase II clinical study for Sintilimab (IBI308) in the maintenance therapy after second-line chemoradiotherapy for local and/or regional recurrent esophageal squamous cell cancer patients |
|
|
| Not yet recruiting | 2 | 22 | | Sintilimab (IBI308) in the maintenance therapy | Shandong Cancer Hospital; Shandong Cancer Hospital, company support and self-funding | esophageal cancer | | | | |
NCT03946969: Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer |
|
|
| Active, not recruiting | 2 | 30 | RoW | Sintilimab, IBI308, Liposomal Paclitaxel + Cisplatin + S-1, PFC | The First Affiliated Hospital with Nanjing Medical University, Innovent Biologics (Suzhou) Co. Ltd. | Esophageal Squamous Cell Carcinoma | 11/21 | 10/22 | | |
ChiCTR2000040345: Single-arm, Phase II exploratory clinical study of Sintilimab combined with platinum-containing chemotherapy for neoadjuvant treatment of esophageal cancer |
|
|
| Not yet recruiting | 2 | 30 | | Immunotherapy and chemotherapy | The Second People's Hospital of Jiaozuo City; The Second People's Hospital of Jiaozuo City, Build together | Esophageal squamous cell carcinoma | | | | |
ChiCTR1900027009: The prospective, open-lable, single-arm, single-center, phase II clinical study for Sintilimab combined with doxorubicin in patients with metastatic/unresectable soft tissue sarcoma |
|
|
| Not yet recruiting | 2 | 35 | | Sintilimab combined with doxorubicin | Henan Cancer Hospital; Henan Cancer Hospital, Hospital funding | soft tissue sarcoma | | | | |
Carpp-1, NCT04882462: Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC. |
|
|
| Not yet recruiting | 2 | 100 | NA | Nimotuzumab, Sintilimab, Chemotherapy drug | The First Affiliated Hospital of Soochow University, Biotech Pharmaceutical Co., Ltd., Cinda Biopharmaceutical (Suzhou) Co., Ltd. | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | 11/21 | 12/22 | | |
NCT04096690: Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma |
|
|
| Recruiting | 2 | 22 | RoW | Pegaspargase, Anti-PD-1 monoclonal antibody, Tyvyt | Ruijin Hospital | Nasal Type Extranodal NK/T-Cell Lymphoma | 12/21 | 12/22 | | |
ChiCTR2000039666: Efficacy and safety of axitinib combined with PD1 inhibitor neoadjuvant treatment of locally advanced renal cell carcinoma: a single center single arm phase II clinical study |
|
|
| Recruiting | 2 | 11 | | sintilimab | Cancer Center of Sun Yat-Sen University; Cancer Center of Sun Yat-Sen University, Innovent Biologics (Suzhou) Co. Ltd. | renal cell carcinoma | | | | |
NCT04769908: Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis |
|
|
| Recruiting | 2 | 40 | RoW | Systemic Chemotherapy, Lenvatinib, Sintilimab | Sun Yat-sen University | ICC | 12/21 | 12/21 | | |
NCT04004572: Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma |
|
|
| Recruiting | 2 | 37 | RoW | LEAP regimen, Pegaspargase, Sintilimab, Anlotinib | Rong Tao | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | 12/21 | 12/22 | | |
NCT03863483: A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy. |
|
|
| Recruiting | 2 | 70 | RoW | Sintilimab, Docetaxel, Pemetrexed, Placebo | Xin-Hua Xu | Nonsquamous Non-Small Cell Lung Cancer | 12/21 | 12/22 | | |
ChiCTR2000031437: Efficacy and Safety of HAIC Combined With Sintilimab and Sorafenib for Advanced HCC |
|
|
| Not yet recruiting | 2 | 40 | | HAIC+Sintilimab+Sorafenib | Department of interventional therapy, cancer hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences, None | Hepatocellular Carcinoma | | | | |
NCT04695470: Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients |
|
|
| Recruiting | 2 | 70 | RoW | Fruquintinib and Sintilimab | Aiping Zhou | Colorectal Cancer | 12/21 | 06/22 | | |
ChiCTR2000031890: A phase II single-arm study for Sintilimab combined with Albumin-bound paclitaxel in the treatment of platinum-resistant recurrent epithelial ovarian cancer/fallopian tube cancer/primary peritoneal adenocarcinoma |
|
|
| Recruiting | 2 | 45 | | chemotherapy and immunotherapy | Beijing Cancer Hospital; Beijing Cancer Hospital, Shijiazhuang Pharmaceutical Group Company, Innovent Biologics, Inc | ovarian cancer/fallopian tube cancer/primary peritoneal adenocarcinoma | | | | |
NCT05029973: HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC |
|
|
| Recruiting | 2 | 30 | RoW | HAIC, Hepatic Artery Infusion Chemotherapy, FOLFOX, Sintilimab, IBI308, Bevacizumab Biosimilar, IBI305 | Tianjin Medical University Cancer Institute and Hospital | Hepatocellular Carcinoma | 01/22 | 11/23 | | |
NCT04514835: A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC |
|
|
| Not yet recruiting | 2 | 44 | RoW | Cisplatin+Capecitabine+Sintilimab | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 01/22 | 01/23 | | |
NCT04231370: Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma |
|
|
| Recruiting | 2 | 20 | RoW | Sintilimab, anti-PD-1-antibody, Lenalidomide, IMids | Beijing Tongren Hospital | NK/T Cell Lymphoma Nos | 02/22 | 12/22 | | |
SAIS, NCT04356872: The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 45 | RoW | Sintilimab, Doxorubicin Hydrochloride, ADM, Ifosfamide, IFO | Fudan University, Zhejiang Cancer Hospital, Tongji Hospital, Xijing Hospital, Shanghai Zhongshan Hospital | Sarcoma, Soft Tissue | 03/22 | 03/23 | | |
NCT04282278: Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor |
|
|
| Recruiting | 2 | 180 | RoW | Camrelizumab/sintilimab+ Standard chemotherapy, Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）, Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy | Hebei Medical University Fourth Hospital | Advanced Solid Tumor | 04/22 | 04/24 | | |
NCT06015035: Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer |
|
|
| Completed | 2 | 17 | RoW | Sintilimab and anlotinib in combination with chemotherapy | Tang-Du Hospital | Sintilimab and Anlotinib in Combination With Chemotherapy | 04/22 | 04/22 | | |
| Recruiting | 2 | 37 | RoW | Sintilimab | Peking Union Medical College Hospital | Carcinoma, Non-Small Cell Lung | 04/22 | 04/23 | | |
SIFOX study, ChiCTR1900028044: Safety and efficacy study of Sintilimab combined with IBI305 and mFOLFOX4 in first-line treatment of advanced hepatocellular carcinoma |
|
|
| Not yet recruiting | 2 | 20 | | Sintilimab combined with IBI305 and mFOLFOX4 | The Third Affiliated Hospital of Sun Yat-Sen University; The Third Affiliated Hospital of Sun Yat-sen University, Innovent Biologics (Suzhou) Co. Ltd. | Hepatocellular carcinoma | | | | |
NCT04831710: Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL |
|
|
| Not yet recruiting | 2 | 83 | RoW | Sintilimab, Tyvyt®, Chidamide, Epidaza | Sun Yat-sen University | Angioimmunoblastic T-cell Lymphoma | 04/22 | 04/23 | | |
ChiCTR2100049267: Phase II clinical study of albumin-paclitaxel + cisplatin/carboplatin combined with bevacizumab and sintilimab in the treatment of stage IVb, recurrent, persistent cervical cancer and endometrial cancer |
|
|
| Not yet recruiting | 2 | 40 | | Chemotherapy + targeted + immunotherapy | Shandong Cancer Hospital; Shandong Cancer Hospital, Free research drugs | Cervical/Endometrial Cancer | | | | |
NCT04602013: Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 53 | RoW | Sintilimab, Sintilizumab, Chemotherapy, albumin-bound paclitaxel, Radiation Therapy | Sichuan Cancer Hospital and Research Institute, General Hospital of Ningxia Medical University, First Affiliated Hospital Xi'an Jiaotong University, Affiliated Hospital of Southwest Medical University, Chongqing Three Gorges Central Hospital | Locally Advanced Esophageal Squamous Cell Carcinoma | 05/22 | 05/22 | | |
NCT04842565: cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria |
|
|
| Completed | 2 | 20 | RoW | Sintilimab, TACE | Fudan University | Hepatocellular Carcinoma | 05/22 | 05/23 | | |
NCT04341857: PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma |
|
|
| Recruiting | 2 | 25 | RoW | PD-1 Monoclonal Antibody(Sintilimab) | Henan Cancer Hospital | Gastric and Esophagogastric Junction Adenocarcinoma | 05/22 | 07/22 | | |
ChiCTR1900022683: Sintilimab plus gemcitabine combined cisplatin and local radiotherapy for primary tumor in the treatment of nasopharyngeal carcinoma with metastasis at first diagnosis:prospected, single-arm, phase II clinical trial |
|
|
| Not yet recruiting | 2 | 32 | | Sintilimab combined with gemcitabine plus cisplatin and primary radiotherapy | West China Hospital, Sichuan University; West China Hospital, Sichuan University, West China Hospital, Sichuan University | nasopharyngeal carcinoma | | | | |
ChiCTR2100046243: Efficacy and safety of HIFU combined with cindilizumab and bevacizumab in the treatment of advanced liver cancer |
|
|
| Recruiting | 2 | 50 | | PD1+ bevacizumab +HIFU | The Second Affiliated Hospital of Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University, Department project fund | Hepatocellular carcinoma | | | | |
NCT04146831: Sintilimab in FH-deficient Renal Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 37 | NA | Sintilimab | West China Hospital | Renal Cell Carcinoma, FH-deficient, Sintilimab | 06/22 | 04/23 | | |
ChiCTR2000035590: Sintilimab combined with Tiggio for maintenance therapy after first-line treatment of advanced biliary tumors: a single-arm, phase II clinical trial |
|
|
| Not yet recruiting | 2 | 65 | | Sintilimab combined with Tiggio regimen | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Innovent Biologics, Inc. presents two courses of Sintilimab for each enrolled patient. | biliary tract carcinoma | | | | |
NCT05174325: Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Sintilimab + chemotherapy | The First Affiliated Hospital of Soochow University, Innovent Biologics (Suzhou) Co. Ltd. | Esophageal Squamous Cell Carcinoma | 06/22 | 07/22 | | |
NCT04535024: The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 60 | RoW | Stereotactic Ablative Radiotherapy (SABR), Sintilimab | Fudan University | Colorectal Cancer | 06/22 | 12/22 | | |
CCICC-002b, NCT04836728: Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer |
|
|
| Not yet recruiting | 2 | 156 | RoW | CIK cell injection, Autologous cytokine-induced killer cells, Sintilimab Injection, PD-1 inhibitor, Pemetrexed, Pemetrexed injection, Albumin paclitaxel, Albumin paclitaxel Injection, Carboplatin, Carboplatin injection | Tianjin Medical University Cancer Institute and Hospital | Non-small Cell Lung Cancer Metastatic, First-line Treatment | 06/22 | 12/23 | | |
NCT03830411: A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy |
|
|
| Recruiting | 2 | 76 | RoW | Sintilimab, IBI308, Docetaxel, Pemetrexed | Xin-Hua Xu | Nonsquamous Non-Small Cell Lung Cancer | 06/22 | 06/22 | | |
ChiCTR1900022003: Exploratory Observational Study for Anlotinib Hydrochloride Combined with Sintilimab Second-line Therapy for Advanced Biliary System Tumor |
|
|
| Recruiting | 2 | 20 | | Anlotinib Hydrochloride Combined with Sintilimab | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, raise independently | Advanced Biliary Tumors | | | | |
ChiCTR2000031183: Sindilizumab and Antinil combined with radiotherapy forunresectable primary hepatocellular carcinoma: A phase II clinical study |
|
|
| Not yet recruiting | 2 | 65 | | Targeted immunity combined with radiotherapy | Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences; Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences, initiator | Liver Cancer | | | | |
NCT04612673: A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC |
|
|
| Not yet recruiting | 2 | 33 | RoW | Sintilimab | China Medical University, China, Shengjing Hospital, The First People's Hospital of Jingzhou, The People's Hospital of Liaoning Province, Liaoning Cancer Hospital & Institute, Anshan Tumor Hospital, Benxi Cental Hospital, The Second Affiliated Hospital of Dalian Medical University, The First Affiliated Hospital of Dalian Medical University | Non-small Cell Lung Cancer | 06/22 | 12/22 | | |
NCT04917770: The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 28 | NA | Sintilimab in combination with Multimodality Radiotherapy | West China Hospital, Chengdu City No.2 People's Hospital, No.3 People's Hospital of Chengdu, Sichuan Provincial People's Hospital, The First People's Hospital of Ziyang, No.5 People's Hospital of Chengdu | Nasopharyngeal Carcinoma | 06/22 | 06/24 | | |
NCT04547452: Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC |
|
|
| Recruiting | 2 | 84 | RoW | Stereotactic body radiation therapy, SBRT, Anti-PD-1 antibody drug named Sintilimab | West China Hospital | Stage IV HCC, Immunotherapy, SBRT | 07/22 | 07/23 | | |
NCT04423185: PLATFORM Study of Precision Medicine for Rare Tumors |
|
|
| Not yet recruiting | 2 | 770 | NA | Almonertinib 110 MG, HS-10296, AMEILE, Dacomitinib 45 MG, Vizimpro, Alectinib 150 MG, Alecensa, Crizotinib 250 MG, Xalkori, Pyrotinib 160/80 MG, SHR-1258, Imatinib 400 MG, Gleevec, Niraparib 200/300 MG, Niraparix, Palbociclib 125mg, Ibrance, Vemurafenib 240 MG, Zelboraf, Sintilimab 100MG, Tyvyt, Atezolizumab 1680 MG, TECENTRIQ | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Rare Tumor | 07/22 | 07/23 | | |
ChiCTR2100047433: Safety and efficacy of cindilizumab + bevacizumab combined with portal vein cancer embolism SBRT in the first-line treatment of primary liver cancer |
|
|
| Recruiting | 2 | 60 | | cindilizumab ;bevacizumab | Shandong Cancer Hospital; Shandong Cancer Hospital, Cinda Biopharmaceutical (Suzhou) Co., Ltd | Hepatocellular carcinoma | | | | |
STOP, NCT04065737: Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization |
|
|
| Not yet recruiting | 2 | 29 | RoW | Sintilimab, IBI308 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Oral Cavity Cancer, Mouth Neoplasm, Precancerous Conditions | 07/22 | 12/22 | | |
NCT04724239: Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma |
|
|
| Active, not recruiting | 2 | 48 | RoW | Sintilimab, Chidamide, IBI305, Bevacizumab | Sun Yat-sen University | Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer | 07/22 | 12/23 | | |
NCT04174781: Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC |
|
|
| Active, not recruiting | 2 | 61 | RoW | Sintilimab, Immunotherapy, Anti-PD-1 therapy, DEB-TACE, Drug-eluting Bead Transarterial Chemoembolization | Zhejiang University | Hepatocellular Carcinoma | 07/22 | 12/22 | | |
NCT04513301: Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study |
|
|
| Recruiting | 2 | 70 | RoW | Sintilimab, Radiotherapy | Shanghai Cancer Hospital, China | Lung Neoplasms | 08/22 | 12/22 | | |
SAARCC, NCT04958473: A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer |
|
|
| Not yet recruiting | 2 | 40 | RoW | Sintilimab, Tyvyt, IBI 308, Axitinib, Inlyta | Tianjin Medical University Second Hospital | Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | 08/22 | 08/25 | | |
NCT04042805: Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 36 | RoW | Sintilimab, IBI308, Lenvatinib | Baocai Xing | Hepatocellular Carcinoma | 08/22 | 08/24 | | |
NCT04140318: Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 60 | RoW | sintilimab, nab-paclitaxel | Chinese Academy of Medical Sciences, Chinese PLA General Hospital, Beijing Friendship Hospital, Beijing Hospital | Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma | 08/22 | 02/23 | | |
NCT04885413: An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients |
|
|
| Recruiting | 2 | 37 | RoW | Niraparib in Combination With Anti-PD1 Antibody, sintilimab | Sun Yat-sen University | Recurrent/ Advanced Stage Endometrial Cancer Patients | 08/22 | 06/23 | | |
NCT04106180: SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC |
|
|
| Recruiting | 2 | 63 | RoW | GM-CSF, Sintilimab, SBRT, Stereotactic body radiation therapy | Fudan University | NSCLC Stage IV | 08/22 | 08/23 | | |
ChiCTR2000036652: Clinical research on PD-1 inhibitor plus Gemcitabine based chemotherapy as the treatment in advanced biliary tract cancer |
|
|
| Completed | 2 | 30 | | Gemcitabine based chemotherapy plus sintilimab | Eastern Hepatobiliary Surgery Hospital Second, Military Medical University, Shanghai, China; Eastern Hepatobiliary Surgery Hospital Second, Military Medical University, Shanghai, China, self-finance | biliary tract cancer | | | | |
NCT04486287: Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 44 | NA | Sintilimab, Tyvyt, IBI 308 | Tianjin Medical University Second Hospital | Oligometastasis, Lung Neoplasms | 09/22 | 09/23 | | |
ChiCTR2000036406: Precise diagnosis and treatment of BRCA mutation-negative platinum-resistant recurrent ovarian cancer guided by CODEX imaging system: a prospective, randomized, controlled study |
|
|
| Not yet recruiting | 2 | 160 | | Paclitaxel, Bevacizumab, Sintilimab ;Paclitaxel, Bevacizumab ;Paclitaxel, Bevacizumab ;Paclitaxel, Bevacizumab | Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Three-year action plan to promote the clinical skills and innovation of municipal hospital | ovarian cancer | | | | |
NCT04258111: IBI310 in Combination With Sintilimab in Patients With DNA Mismatch Repair Deficient (dMMR)/Microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 4 | RoW | IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody) | Innovent Biologics (Suzhou) Co. Ltd. | Colorectal Cancer | 10/22 | 05/23 | | |
ChiCTR2000035072: Phase II single-arm study for Sintilimab combined with Albumin-bound paclitaxel and Anlotinib in the treatment of platinum-resistant recurrent epithelial ovarian cancer/fallopian tube cancer/primary peritoneal adenocarcinoma |
|
|
| Not yet recruiting | 2 | 30 | | Sintilimab combined with Albumin-bound paclitaxel and Anlotinib | Cancer center, the First Hospital of Jilin University; The First Hospital of Jilin University, CSCO foundation | Ovarian Cancer | | | | |
NCT04764006: Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study |
|
|
| Recruiting | 2 | 10 | RoW | Surufatinib, HMPL-012 | Fujian Cancer Hospital | Advanced Colorectal Cancer | 10/22 | 11/23 | | |
ChiCTR2000038713: A prospective, one-arm phase II clinical study of Sintilimab with Irinotecan in the treatment of advanced pancreatic cancer |
|
|
| Not yet recruiting | 2 | 33 | | Sintilimab with Irinotecan | Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences, Researcher self-raising | pancreatic cancer | | | | |
ChiCTR1900028540: Efficacy and Safety Study for Paclitaxel plus Cisplatin Chemotherapy with Sintilimab in Women with Persistent, Recurent, or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 54 | | paclitaxel+cisplatin+sintilimab | Peking University Cancer Hospital; Peking University Cancer Hospital, Xisike Clinial Oncology Research Foundation | Cervical Cancer | | | | |
ChiCTR2000040223: A single-arm, single-center prospective study of the efficacy and safety of Sintilimab in combination with conventional antitumor therapy for recurrent or metastatic cervical, endometrial, and ovarian cancers |
|
|
| Not yet recruiting | 2 | 30 | | Sintilimab | Second People's Hospital of Changzhou City; Second People's Hospital of Changzhou City, self-collected | cervical cancer、endometrial, and ovarian cancer | | | | |
ChiCTR2000039748: Radioactive particle brachytherapy combined with sintilimab in the treatment of refractory solid malignant tumors: a prospective phase II clinical study |
|
|
| Recruiting | 2 | 44 | | Stereotactic brachytherapy (SABT) combined with immune checkpoint inhibitor-sintilimab | The Affiliated Zhongshan Hospital of Dalian University; The Affiliated Zhongshan Hospital of Dalian University, Hospital funding | Refractory solid malignant tumor | | | | |
NCT05113355: Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm |
|
|
| Recruiting | 2 | 23 | RoW | Chidamide, Epidaza, Sintilimab, Tyvyt | Peking Union Medical College Hospital, The First Affiliated Hospital of Xiamen University, Harbin Medical University | Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma, Neuroendocrine Neoplasm | 11/22 | 11/24 | | |
BBCAPX-II, NCT04194359: Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 25 | RoW | Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine | Second Affiliated Hospital, School of Medicine, Zhejiang University | Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable | 11/22 | 12/23 | | |
NCT05008666: Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH |
|
|
| Not yet recruiting | 2 | 37 | RoW | Sintilimab, Chidamide, Azacitidine, L-DEP | Sun Yat-sen University | Safety and Efficacy | 11/22 | 04/23 | | |
ChiCTR2100053389: Efficacy and safety of Sintilimab combined with platinum-containing chemotherapy in the treatment of resectable stage IB-IIIA non-small cell lung cancer |
|
|
| Recruiting | 2 | 30 | | sintilimab combined with platinum-containing dual drug chemotherapy | The Second Affiliated Hospital of Shandong First Medical University; The Second Affiliated Hospital of Shandong First Medical University, Self-funded | Lung cancer | | | | |
NCT04213170: Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 60 | RoW | sintilimab, bevacizumab | Sun Yat-sen University | Brain Metastases, Non Small Cell Lung Cancer, Sintilimab, Bevacizumab | 12/22 | 12/22 | | |
ChiCTR1900021908: Single-center, one-arm, prospective phase II clinical study of the efficacy and safety of sintilimab in the treatment of persistent, recurrent, and metastatic cervical cancer |
|
|
| Not yet recruiting | 2 | 42 | | sintilimab 200mg ivgtt q21d 2 years | Fujian Provincial Cancer Hospital; Fujian Provincial Cancer Hospital, Wu Jieping Medical Foundation Clinical research special fund | Cervical Carcinoma | | | | |
CO-STAR, NCT04267549: Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer |
|
|
| Active, not recruiting | 2 | 47 | RoW | sintilimab, Tyvyt, apatinib, S1, Nab paclitaxel | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer Stage IV | 12/22 | 08/23 | | |
NCT04296786: Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study |
|
|
| Recruiting | 2 | 52 | RoW | Sintilimab, Chidamide | Peking Union Medical College Hospital, Peking University Third Hospital, Beijing Longfu Hospital, Dongzhimen Hospital, Beijing | Cutaneous T-cell Lymphoma | 12/22 | 12/24 | | |
NCT04663763: Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer |
|
|
| Not yet recruiting | 2 | 40 | RoW | PD-1 antibody, Sintilimab, Capecitabine, Oxaliplatin | Zhejiang Cancer Hospital | Locally Advanced Rectal Cancer | 12/22 | 12/25 | | |
iCSDeR, NCT05476965: Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 20 | RoW | induction therapy; surgery; radiotherapy | Hubei Cancer Hospital | Head and Neck Squamous Cell Carcinoma, Radiotherapy, Immunotherapy, Surgery | 12/22 | 06/24 | | |
ChiCTR2100045992: Efficacy and safety of Sintilimab combined with albumin paclitaxel plus platinum chemotherapy versus albumin paclitaxel plus platinum in neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a randomized controlled trial |
|
|
| Recruiting | 2 | 40 | | Preoperative concurrent chemotherapy with albumin paclitaxel, cisplatin and cindilizumab ;Preoperative neoadjuvant chemotherapy with albumin, paclitaxel and cisplatin | Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital, Wu Jieping Medical Foundation | Esophageal squamous cell carcinoma | | | | |
NCT04659434: Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL |
|
|
| Not yet recruiting | 2 | 51 | RoW | Sintilimab, IBI308 | Qian Wenbin | Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 12/22 | 12/25 | | |
| Recruiting | 2 | 400 | RoW | Avitinib Maleate, AC0010, Afatinib, Giotrif, Crizotinib, Xalkori, X-396, ensartinib, Chidamide, Epidaza, Pyrotinib Maleate, SHR1258, AZD3759, Pirotinib, KBP-5209, Nimotuzumab, Pemetrexed, LY231514, Cisplatin, CDDP, Sintilimab, Gemcitabine, LY188011, Carboplatin, NSC 241240 | Guangdong Association of Clinical Trials, Chinese Thoracic Oncology Group | Carcinoma, Non-Small-Cell Lung | 12/22 | 12/24 | | |
ChiCTR2000040673: A prospective, single-center, phase II study of sintilimab combined with chemotherapy as induction therapy for potentially resectable stage IIIB non-small cell lung cancer |
|
|
| Recruiting | 2 | 30 | | Sintilimab Combined With Double Platinum Based Chemotherapy | Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Hospital; Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Hospital, Innovent Biopharmaceutical (Suzhou) Co., Ltd. | Non-small cell lung cancer | | | | |
PLATIC, NCT04814043: PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial |
|
|
| Recruiting | 2 | 57 | RoW | PD-1 inhibitor, lenvatinib, TACE-HAIC | Sun Yat-sen University | Hepatocellular Carcinoma | 12/22 | 12/23 | | |
ALTER-C201, ChiCTR1900023015: Single-center, one-arm, prospective phase II clinical study of the efficacy and safety of sintilimab combined with anlotinib in the treatment of persistent, recurrent, and metastatic cervical cancer |
|
|
| Recruiting | 2 | 42 | | sintilimab 200mg ivgtt q21d; anlotinib 10mg before breakfast oral qd for 14 days, 7 days of withdrawal, 21 days for a course of treatment; treatment for 2 years | Fujian Provincial Cancer Hospital; Fujian Provincial Cancer Hospital, Wu Jieping Medical Foundation Clinical research special fund | Cervical Carcinoma | | | | |
ChiCTR1900026448: Phase II clinical study for Sintilimab in the maintenance therapy after first-line chemotherapy of advanced lung squamous cell carcinoma |
|
|
| Not yet recruiting | 2 | 40 | | Sintilimab for maintenance therapy | Fujian Province Cancer Hospital; Fujian Province Cancer Hospital, none | Lung cancer | | | | |
NCT04279379: Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma |
|
|
| Recruiting | 2 | 20 | RoW | Sintilimab, anti-PD-1-antibody, Decitabine, hypomethylating agents | Beijing Tongren Hospital | Extranodal NK/T-cell Lymphoma | 12/22 | 12/22 | | |
NCT04548440: Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients |
|
|
| Completed | 2 | 50 | RoW | Sintilimab, Anti-PDCD1 monoclonal antibody IBI308, Tyvyt, Nab paclitaxel, Nanoparticle Albumin-Bound Paclitaxel, Abraxane, Cisplatin, CDDP, Platinol | Sun Yat-sen University, Innovent Biologics (Suzhou) Co. Ltd., CSPC Pharmaceutical Group Limited | Esophageal Squamous Cell Carcinoma | 12/22 | 12/22 | | |
ChiCTR2000040318: The safety and efficacy of Sindili in the perioperative treatment of locally advanced rectal cancer: single-arm, single-center study |
|
|
| Not yet recruiting | 2 | 35 | | Sintilimab + Radiation therapy + Oxaliplatin + capecitabine | Xuzhou Central Hospital; Xuzhou Central Hospital, self-financing | rectal cancer | | | | |
NCT04722718: Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer |
|
|
| Recruiting | 2 | 34 | RoW | Sintilimab+Apatinib+Albumin-Bound Paclitaxel(Nab-Paclitaxel)+Carboplatin | Jiuda Zhao | Breast Cancer | 12/22 | 01/23 | | |
| Not yet recruiting | 2 | 23 | NA | Sintilimab, Anlotinib hydrochloride | Zhejiang Cancer Hospital | Small Cell Lung Cancer Extensive Stage | 12/22 | 12/23 | | |
NCT05402722: Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Eribulin, Halaven, anti-PD-1 antibody | Beijing 302 Hospital | TNBC - Triple-Negative Breast Cancer | 12/22 | 06/23 | | |
ChiCTR2100049290: A single-arm, open-label, single-center phase II clinical study of sintilimab combined with bevacizumab in the treatment of recurrent or metastatic cervical cancer |
|
|
| Recruiting | 2 | 52 | | Sintilimab in combination with bevacizumab | Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, Innovent Biologics (Suzhou) Co., Ltd. | cervical cancer | | | | |
